Home › Mercks Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Nave Adults
 

Keywords :   


Mercks Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Nave Adults

2014-03-05 18:15:00| Merck.com - Research & Development News

Dateline City: BOSTON Merck Plans to Initiate Phase 3 Clinical Development Program in Second Half of 2014 BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today presented data from the dose-ranging portion of an ongoing Phase 2B clinical trial of doravirine, the companys investigational next-generation, non-nucleoside reverse transcriptase inhibitor (NNRTI), at the 21st Conference on Retroviruses and Opportunistic Infections (CROI). Language: English Contact: MerckMedia:Caroline Lappetito, 267-305-7639orSarra Herzog, 201-669-6570orInvestor:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: study activity phase adults

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
20.05IMDA launches annual IMDA Awards Competition
20.05Registration opens for FTAs Fall Technical Conference 2024
20.05Voting begins for Colored By INX Can Design Contest
20.05New Study Highlights Biodegradability of Cotton and Cellulosic Microfibers
20.05New ACA-Published Industry Market Analysis for the Paint & Coatings Industry Now Available
20.05Ulta Beauty Launches Same-Day Delivery with DoorDash
20.05Nivea Crmes Limited-Edition Pride Tin Heralds New Initiative with PFLAG
20.05Sheboygan Paint Company Appoints New Technical Sales Representative
More »